<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="samd9l-ap" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">samd9l-ap</book-part-id>
      <title-group>
        <title><italic toggle="yes">SAMD9L</italic>-Related Ataxia-Pancytopenia Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Phowthongkum</surname>
            <given-names>Prasit</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="samd9l-ap.Tc.aff1"/>
          <email>praspowt@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Dong-Hui</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="samd9l-ap.Tc.aff1"/>
          <email>cdhui@uw.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Raskind</surname>
            <given-names>Wendy H</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="samd9l-ap.Tc.aff1"/>
          <email>wendyrun@uw.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bird</surname>
            <given-names>Thomas</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="samd9l-ap.Tc.aff1"/>
          <email>tomnroz@uw.edu</email>
        </contrib>
      </contrib-group>
      <aff id="samd9l-ap.Tc.aff1">University of Washington<break/>Seattle, Washington</aff>
      <pub-history>
        <date date-type="created">
          <day>1</day>
          <month>6</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="drrs" document-type="chapter">
<italic toggle="yes">SALL4</italic>-Related Disorders</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="gefs" document-type="chapter">
<italic toggle="yes">SCN1A</italic>-Related Seizure Disorders</related-object>
      <abstract id="samd9l-ap.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">SAMD9L</italic>-related ataxia-pancytopenia (ATXPC) syndrome is characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to marrow failure, myelodysplasia, and myeloid leukemia, sometimes associated with monosomy 7. The onset of hematologic abnormalities has been reported as early as age three months. The cytopenias in all cell lineages ranged from mild to very severe. Onset of neurologic impairment is variable. Nystagmus, dysmetria, increased deep tendon reflexes, and clonus are common. Gait impairment and other neurologic abnormalities are slowly progressive.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome is established in a proband by identification of a heterozygous germline pathogenic variant in <italic toggle="yes">SAMD9L</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Red cell or platelet transfusions as needed for cytopenias; evaluation and treatment for additional unrelated causes of anemia; bone marrow transplantation and/or chemotherapy for myelodysplasia and leukemia; supportive management for ataxia to prevent falls and injury.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual complete blood count with more frequent monitoring for any identified cytopenia; prompt evaluation for clinical signs or symptoms of cytopenia; annual evaluation of gait, coordination, and speech.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Nonsteroidal anti-inflammatory agents, anticoagulants, and thrombolytic agents are contraindicated if thrombocytopenia is present and should be used with caution given the fluctuating nature of the cytopenias; avoid alcohol and medications that cause sedation, which can increase problems with gait and coordination.</p>
        </sec>
        <sec>
          <title>Genetic Counseling</title>
          <p><italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome is inherited in an autosomal dominant manner. To date, no individuals diagnosed with <italic toggle="yes">SAMD9L</italic>-related ataxia-pancytopenia have the disorder as the result of a <italic toggle="yes">de novo SAMD9L</italic> pathogenic variant. Each child of an individual with <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome has a 50% chance of inheriting the <italic toggle="yes">SAMD9L</italic> pathogenic variant; intrafamilial clinical variability has been observed. Once the <italic toggle="yes">SAMD9L</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk for <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome and preimplantation genetic diagnosis are possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="samd9l-ap.Diagnosis">
        <title>Diagnosis</title>
        <sec id="samd9l-ap.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">SAMD9L</italic>-related ataxia-pancytopenia (ATXPC) syndrome can be considered in an individual with any of the following clinical features, radiographic features, or family history, and suspected if more than one of these characteristics is present:</p>
          <list list-type="bullet">
            <list-item>
              <p>Cerebellar ataxia</p>
            </list-item>
            <list-item>
              <p>Variable hematopoietic cytopenias affecting one or more lineages (e.g., anemia, neutropenia, thrombocytopenia)</p>
            </list-item>
            <list-item>
              <p>Myeloid leukemia or myelodysplasia with partial or complete monosomy 7</p>
            </list-item>
            <list-item>
              <p>Cerebellar atrophy and white matter changes on brain MRI examination</p>
            </list-item>
            <list-item>
              <p>Family history of any of the above clinical or radiographic features</p>
            </list-item>
          </list>
        </sec>
        <sec id="samd9l-ap.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>No formal clinical criteria for <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome have been established. The diagnosis of <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome <bold>is established</bold> in a proband by identification of a heterozygous germline pathogenic variant in <italic toggle="yes">SAMD9L</italic> on molecular genetic testing (see <xref ref-type="table" rid="samd9l-ap.T.molecular_genetic_testing_us">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Perform sequence analysis of <italic toggle="yes">SAMD9L</italic>.</p>
              <p>Note: <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome is postulated to occur through a gain-of-function mechanism. Large intragenic deletion or duplication has not been reported; testing for intragenic deletions or duplication is not indicated.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">SAMD9L</italic> and other genes of interest (see <xref ref-type="sec" rid="samd9l-ap.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="samd9l-ap.T.molecular_genetic_testing_us" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">SAMD9L</italic>-Related Ataxia-Pancytopenia Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">SAMD9L</italic>
                  </td>
                  <td headers="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4/4 families&#x000a0;<sup>4,&#x000a0;5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_samd9l-ap.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="samd9l-ap.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="samd9l-ap" object-id="samd9l-ap.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="samd9l-ap.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="samd9l-ap.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="samd9l-ap.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="samd9l-ap.TF.1.4">
                <label>4. </label>
                <p>
                  <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al [2016]</xref>
                </p>
              </fn>
              <fn id="samd9l-ap.TF.1.5">
                <label>5. </label>
                <p>
                  <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al [2017]</xref>
                </p>
              </fn>
              <fn id="samd9l-ap.TF.1.6">
                <label>6. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="samd9l-ap.TF.1.7">
                <label>7. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="samd9l-ap.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="samd9l-ap.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">SAMD9L</italic>-related ataxia-pancytopenia (ATXPC) syndrome is a rare autosomal dominant condition characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to marrow failure, myelodysplasia, and myeloid leukemia, sometimes associated with monosomy 7. Manifestations usually have onset in childhood and hematologic impairment can be severe, mimicking aplastic anemia or idiopathic thrombocytopenia purpura. There is marked inter- and intrafamilial variability in age of onset, severity of neurologic and hematologic abnormalities, and rate of progression. Only four families with molecularly confirmed <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome in a total of 25 individuals have been described [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1978.933">Li et al 1978</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.li.1981.189">Li et al 1981</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]; a fifth published family with a consistent phenotype is unavailable for molecular confirmation [<xref ref-type="bibr" rid="samd9l-ap.REF.daghistani.1989.108">Daghistani et al 1989</xref>].</p>
          <p><bold>Hematologic manifestations.</bold> Hematologic abnormalities are variable and can be intermittent. The onset of hematologic abnormalities has been reported as early as age three months.</p>
          <p>The cytopenias in all cell lineages ranged from mild to very severe. Anemia and/or mild macrocytosis (maximum recorded mean corpuscular volume [MCV]: 108 fl) were documented in many affected individuals. Immunodeficiency was documented in one family [<xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]. Non-leukemic marrows were hypoplastic in three individuals examined. Partial or complete monosomy 7 was found in marrow cells from four affected individuals, one of whom eventually developed leukemia [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1981.189">Li et al 1981</xref>]; two had myelodysplasia [<xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]. The effect of the disease on the hematopoietic system accounts for the increased mortality. In the four molecularly confirmed families, five affected individuals died in childhood from marrow failure and/or acute myeloid leukemia [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1981.189">Li et al 1981</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>]. Two children with myelodysplasia received matched unrelated marrow transplants and were alive 1.5 and seven years later [<xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>].</p>
          <p>In the family suspected to have ATXPC syndrome, one of three affected people had pancytopenia at age five years with mild macrocytosis (MCV 109 fl), decreased marrow cellularity, and monosomy 7 identified in marrow cells. This child died from acute myeloid leukemia that developed one year following diagnosis [<xref ref-type="bibr" rid="samd9l-ap.REF.daghistani.1989.108">Daghistani et al 1989</xref>].</p>
          <p><bold>Neurologic manifestations.</bold> Neurologic involvement was observed in all individuals with <italic toggle="yes">SAMD9L</italic> pathogenic variants who were carefully examined. Two individuals with<italic toggle="yes">SAMD9L</italic> pathogenic variants were not assessed neurologically [<xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>] and one individual who was not noted to have neurologic problems during life had cerebellar atrophy detected on autopsy [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>]. Onset of neurologic impairment ranged from infancy to 62 years. Horizontal and vertical nystagmus and dysmetria were evident in most individuals. Deep tendon reflexes were usually increased, ankle clonus was easily elicited, and some affected individuals had extensor plantar responses [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1978.933">Li et al 1978</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]. Strength and sensation to touch and proprioception were preserved, but one individual had decreased vibration sense in the lower extremities [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1978.933">Li et al 1978</xref>]. Gait impairment and other neurologic abnormalities were slowly progressive. Some individuals eventually require a wheelchair [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>].</p>
          <p>The severities of hematologic and neurologic abnormalities are not concordant. An individual who died at age 16 years from a retroperitoneal bleed secondary to thrombocytopenia had no clinically reported neurologic manifestations, despite the presence of cerebellar atrophy. Several individuals had moderate to severe neurologic involvement with only mild or undetected hematologic involvement [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1981.189">Li et al 1981</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>].</p>
          <p><bold>Neuroimaging and neuropathology.</bold> Eight individuals with a range of neurologic manifestations have been evaluated by brain imaging or autopsy. Marked cerebellar atrophy and loss of Purkinje cells were detected in four individuals, age seven to 16 years, in two families whose brains were examined post mortem. Moderate loss of neurons in the inferior olives and central nuclei was noted in two of these individuals [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1981.189">Li et al 1981</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>]. CT imaging of two of these children and their father revealed moderate to marked cerebellar atrophy at a time when their ataxia was described as mild to moderate [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1981.189">Li et al 1981</xref>]. At age 54 years, the surviving sib in this family had moderately severe ataxia and required a walker to ambulate. Brain MRI at age 52 years showed severe diffuse cerebellar atrophy as well as diffuse bilateral white matter signals throughout the cerebrum [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>].</p>
          <p>In the second family reported by <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al [2016]</xref>, brain MRIs revealed marked cerebellar degeneration, pronounced in the midline, in a man age 32 years with severe ataxia, and moderate midline cerebellar atrophy in his sister age 38 years who had only mild clinical manifestations. Cerebellar atrophy and white matter abnormalities were also noted on MRI of two individuals reported by <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al [2017]</xref>.</p>
        </sec>
        <sec id="samd9l-ap.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>As only four families with identified pathogenic variants in <italic toggle="yes">SAMD9L</italic> have been reported, it is not possible to determine if there are genotype-phenotype correlations. Two of six affected individuals with pathogenic variant <xref ref-type="table" rid="samd9l-ap.T.samd9l_pathogenic_variants_d">p.Cys1196Ser</xref> [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1978.933">Li et al 1978</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.li.1981.189">Li et al 1981</xref>] and none of 17 with any of the other three known pathogenic variants [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>] has developed acute leukemia to date, but this tally does not include the two individuals who received marrow transplantation for myelodysplasia [<xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]. Somatic mosaicism for loss of the <italic toggle="yes">SAMD9L</italic> pathogenic variant has been documented in hematopoietic tissues of some individuals in three of the families [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]. It is speculated that the presence of a clone that has uniparental disomy for the normal allele may ameliorate the severity of the hematologic manifestations [<xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>].</p>
        </sec>
        <sec id="samd9l-ap.Penetrance">
          <title>Penetrance</title>
          <p>To date, all 24 carefully assessed affected individuals in the four families with pathogenic variants in <italic toggle="yes">SAMD9L</italic> exhibited clinical manifestations. One individual without hematologic cytopenias was not neurologically examined. Expressivity of both hematologic and neurologic manifestations is extremely variable and shows no difference for males and females.</p>
        </sec>
        <sec id="samd9l-ap.Nomenclature">
          <title>Nomenclature</title>
          <p>The disorder was initially called myelocerebellar syndrome by <xref ref-type="bibr" rid="samd9l-ap.REF.li.1978.933">Li et al [1978]</xref>.</p>
        </sec>
        <sec id="samd9l-ap.Prevalence">
          <title>Prevalence</title>
          <p>True prevalence is unknown, but the disorder is extremely rare. To the authors&#x02019; knowledge, only four families with molecularly confirmed ataxia-pancytopenia syndrome have been described in the scientific literature [<xref ref-type="bibr" rid="samd9l-ap.REF.li.1978.933">Li et al 1978</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>].</p>
        </sec>
      </sec>
      <sec id="samd9l-ap.Genetically_Related_Allelic_Di">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with germline pathogenic variants in <italic toggle="yes">SAMD9L</italic>.</p>
      </sec>
      <sec id="samd9l-ap.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>As with other ataxias, it is important to consider acquired causes, as they may be amenable to targeted treatment, and other inherited cerebellar ataxias, as there is considerable overlap in neurologic manifestations (see <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Ataxia Overview</related-object>).</p>
        <p>Because the prominent medical problem in many individuals with ATXPC syndrome is often hematopoietic cytopenias, and neurologic impairment may be minimal, acquired bone marrow failure syndromes such as aplastic anemia or idiopathic thrombocytopenia purpura would also be included in the differential diagnosis.</p>
        <table-wrap id="samd9l-ap.T.disorders_to_consider_in_the" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Disorders to Consider in the Differential Diagnosis of <italic toggle="yes">SAMD9L</italic>-Related Ataxia-Pancytopenia Syndrome</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Disorder</th>
                <th id="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene(s)</th>
                <th id="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">MOI</th>
                <th id="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Hematologic Manifestations</th>
                <th id="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Neurologic Manifestations</th>
                <th id="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Other</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="sider-anemia" document-type="chapter">X-linked sideroblastic anemia and ataxia</related-object>
                </td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">ABCB7</italic>
                </td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Moderate hypochromic &#x00026; microcytic anemia w/out progression to marrow failure</p></list-item><list-item><p>Not associated w/malignancy</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Spinocerebellar syndrome in males&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="ataxia-telangiectas" document-type="chapter">Ataxia-telangiectasia</related-object>
                </td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">ATM</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Bone marrow failure</p></list-item><list-item><p>Increased risk for malignancy, particularly lymphocytic leukemia &#x00026; lymphoma</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Progressive cerebellar ataxia, oculomotor apraxia, choreoathetosis</p></list-item><list-item><p>Early-onset dystonia in non-classic form</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Immunodeficiency</p></list-item><list-item><p>Sensitivity to ionizing radiation</p></list-item><list-item><p>Telangiectasias</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="fa" document-type="chapter">Fanconi anemia</related-object>
                </td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR<break/>AD<break/>XL</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Progressive bone marrow failure</p></list-item><list-item><p>Myelodysplasia</p></list-item><list-item><p>Acute myeloid leukemia</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Microcephaly</p></list-item><list-item><p>Ophthalmic abnormalities</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Solid tumors</p></list-item><list-item><p>Congenital abnormalities&#x000a0;<sup>3</sup></p></list-item><list-item><p>Chromosome breakage/radial forms on lymphocyte cytogenetic testing w/DEB &#x00026; MMC</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="dkc" document-type="chapter">Dyskeratosis congenita</related-object>
                </td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 4</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">XL<break/>AD<break/>AR</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Progressive bone marrow failure</p></list-item><list-item><p>Myelodysplasia</p></list-item><list-item><p>Acute myeloid leukemia</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Normal psychomotor development &#x00026; neurologic function in most persons; see footnote 5 for exceptions</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Dysplastic nails</p></list-item><list-item><p>Lacy reticular pigmentation</p></list-item><list-item><p>Oral leukoplakia</p></list-item><list-item><p>Squamous cell carcinomas</p></list-item><list-item><p>Other solid tumors</p></list-item><list-item><p>Pulmonary fibrosis</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="mono7-mds" document-type="chapter">Familial monosomy 7 syndrome</related-object>
                </td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">n/a</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Bone marrow insufficiency/failure</p></list-item><list-item><p>Acute myeloid leukemia</p></list-item><list-item><p>Myelodysplasia</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">None</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">MIRAGE syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/617053">617053</ext-link>)</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SAMD9</italic>
                </td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Myelodysplasia</p></list-item><list-item><p>Cytopenias</p></list-item></list>
</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Cognitive impairment</td>
                <td headers="hd_h_samd9l-ap.T.disorders_to_consider_in_the_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Adrenal hypoplasia</p></list-item><list-item><p>Growth restriction</p></list-item><list-item><p>Enteropathy</p></list-item><list-item><p>Genital abnormalities</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>DEB = diepoxybutane</p>
            </fn>
            <fn>
              <p>MMC = mitomycin C</p>
            </fn>
            <fn>
              <p>MOI = mode of inheritance</p>
            </fn>
            <fn>
              <p>AD = autosomal dominant</p>
            </fn>
            <fn>
              <p>AR = autosomal recessive</p>
            </fn>
            <fn>
              <p>XL = X-linked</p>
            </fn>
            <fn id="samd9l-ap.TF.2.1">
              <label>1. </label>
              <p>Spinocerebellar syndrome in males manifest primarily as delayed walking, ataxia evident in early childhood, dysmetria, and dysdiadochokinesis. When present the intention tremor is mild and the dysarthria is mild to moderately severe. The ataxia has been described as either non-progressive or slowly progressive.</p>
            </fn>
            <fn id="samd9l-ap.TF.2.2">
              <label>2. </label>
              <p>Genes known to be associated with Fanconi anemia include <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">BRIP1</italic>, <italic toggle="yes">FANCA</italic>, <italic toggle="yes">FANCB</italic>, <italic toggle="yes">FANCC</italic>, <italic toggle="yes">FANCD2</italic>, <italic toggle="yes">FANCE</italic>, <italic toggle="yes">FANCF</italic>, <italic toggle="yes">FANCG</italic>, <italic toggle="yes">FANCI</italic>, <italic toggle="yes">FANCL</italic>, <italic toggle="yes">FANCM</italic>, <italic toggle="yes">PALB2</italic>, <italic toggle="yes">RAD51C</italic>, <italic toggle="yes">SLX4</italic>, and <italic toggle="yes">UBE2T</italic>.</p>
            </fn>
            <fn id="samd9l-ap.TF.2.3">
              <label>3. </label>
              <p>The majority of individuals with FA have congenital abnormalities, most commonly short stature and skeletal, craniofacial, and genitourinary tract malformations. Abnormal skin pigmentation and microcephaly are also common. Other anomalies include developmental delay, hearing loss, congenital heart disease, and CNS anomalies.</p>
            </fn>
            <fn id="samd9l-ap.TF.2.4">
              <label>4. </label>
              <p>To date, <italic toggle="yes">ACD</italic>, <italic toggle="yes">CTC1</italic>, <italic toggle="yes">DKC1</italic>, <italic toggle="yes">NHP2</italic>, <italic toggle="yes">NOP10</italic>, <italic toggle="yes">PARN</italic>, <italic toggle="yes">RTEL1</italic>, <italic toggle="yes">TERC</italic>, <italic toggle="yes">TERT</italic>, <italic toggle="yes">TINF2</italic>, and <italic toggle="yes">WRAP53</italic> are the genes in which pathogenic variants are known to cause dyskeratosis congenita.</p>
            </fn>
            <fn id="samd9l-ap.TF.2.5">
              <label>5. </label>
              <p>Significant developmental delay is present in the two clinical variants &#x02013; Hoyeraal-Hreidarsson syndrome and Revesz syndrome &#x02013; in which additional findings include, respectively: cerebellar hypoplasia and ataxia; and bilateral exudative retinopathy and intracranial calcifications.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="samd9l-ap.Management">
        <title>Management</title>
        <sec id="samd9l-ap.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">SAMD9L</italic>-related ataxia-pancytopenia (ATXPC) syndrome, the following evaluations are recommended if they have not already been completed:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medical history and physical examination including neurologic examination</p>
            </list-item>
            <list-item>
              <p>Brain MRI examination and referral to a neurologist</p>
            </list-item>
            <list-item>
              <p>Complete blood count with differential</p>
            </list-item>
            <list-item>
              <p>Referral to a hematologist/oncologist; bone marrow examination including chromosome 7-targeted FISH if hematologic abnormalities are more than minimal</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="samd9l-ap.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>
            <bold>Hematologic manifestations</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Management of hematologic impairment is based on the severity of cytopenias and consists of red cell or platelet transfusions as needed.</p>
            </list-item>
            <list-item>
              <p>Evaluate and treat for unrelated causes of anemia such as iron and vitamin deficiencies.</p>
            </list-item>
            <list-item>
              <p>Marrow transplantation for myelodysplasia was successful in two individuals to date.</p>
            </list-item>
          </list>
          <p>Note: There are no data to support use of erythropoietin or granulocyte-stimulating factor in <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome; these growth factors may increase the risk for myelodysplasia and myeloid leukemia.</p>
          <p><bold>Neurologic manifestations.</bold> Management of ataxia is supportive, as there is no known therapy to delay or halt the progression of the disease.</p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals should continue to be active and use canes and walkers to prevent falls.</p>
            </list-item>
            <list-item>
              <p>Modification of the home with such conveniences as grab bars, raised toilet seats, and ramps to accommodate motorized chairs may be necessary.</p>
            </list-item>
            <list-item>
              <p>Weight control is important because obesity can exacerbate difficulties with ambulation and mobility.</p>
            </list-item>
          </list>
        </sec>
        <sec id="samd9l-ap.Surveillance">
          <title>Surveillance</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete blood count annually. If cytopenias are identified these should be monitored more frequently.</p>
            </list-item>
            <list-item>
              <p>Patient/family education to seek prompt clinical evaluation if any signs or symptoms suggestive of hematopoietic cytopenia develop (e.g., fatigue, pallor, unexpected bleeding, recurrent infections).</p>
            </list-item>
            <list-item>
              <p>Annual evaluation of gait, coordination, and speech.</p>
            </list-item>
          </list>
        </sec>
        <sec id="samd9l-ap.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Nonsteroidal anti-inflammatory agents, anticoagulants, and thrombolytic agents are contraindicated if thrombocytopenia is present and should be used with caution given the fluctuating nature of the cytopenias.</p>
          <p>Avoid consuming alcohol and medications that cause sedation, which can increase problems with gait and coordination.</p>
        </sec>
        <sec id="samd9l-ap.Evaluation_of_Relatives_at_Ris">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an affected individual by molecular genetic testing of the <italic toggle="yes">SAMD9L</italic> pathogenic variant in the family in order to identify as early as possible those who would benefit from hematologic surveillance and prompt initiation of treatment for severe cytopenias and myelodysplasia.</p>
          <p>See <xref ref-type="sec" rid="samd9l-ap.Related_Genetic_Counseling_Iss">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="samd9l-ap.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>There is no information of the effect of pregnancy on manifestations of <italic toggle="yes">SAMD9L-</italic>related ATXPC syndrome. Anemia, thrombocytopenia, or neutropenia may increase the risk of pregnancy complications.</p>
        </sec>
        <sec id="samd9l-ap.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="samd9l-ap.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="samd9l-ap.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">SAMD9L</italic>-related ataxia-pancytopenia (ATXPC) syndrome is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="samd9l-ap.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>All affected individuals (for whom relevant parental information was available) in the four families with confirmed <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome have an affected parent. Marked intrafamilial variation in terms of age of onset, neurologic manifestations, and hematologic abnormalities is reported in all of these families.</p>
            </list-item>
            <list-item>
              <p>To date, no individuals diagnosed with <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome have the disorder as the result of a <italic toggle="yes">de novo SAMD9L</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of apparently asymptomatic parents of a proband include <italic toggle="yes">SAMD9L</italic> molecular genetic testing.</p>
            </list-item>
            <list-item>
              <p>Theoretically, the family history of an individual diagnosed with <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Although not yet definitively observed, reduced penetrance is possible. Therefore, an apparently negative family history cannot be confirmed unless molecular genetic testing has been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband is heterozygous for the <italic toggle="yes">SAMD9L</italic> pathogenic variant, the risk to the sibs of inheriting the variant is 50%. Intrafamilial clinical variability has been observed (see <xref ref-type="sec" rid="samd9l-ap.Clinical_Description">Clinical Description</xref>).</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">SAMD9L</italic> pathogenic variant found in the proband is not detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of the general population because of the possibility of either parental germline mosaicism for the <italic toggle="yes">SAMD9L</italic> pathogenic variant or parental revertant mosaicism for loss of the <italic toggle="yes">SAMD9L</italic> pathogenic variant (see <xref ref-type="sec" rid="samd9l-ap.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>).</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome has a 50% chance of inheriting the <italic toggle="yes">SAMD9L</italic> pathogenic variant; intrafamilial clinical variability has been observed (see <xref ref-type="sec" rid="samd9l-ap.Clinical_Description">Clinical Description</xref>).</p>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents: if a parent has the <italic toggle="yes">SAMD9L</italic> pathogenic variant, his or her family members may be at risk.</p>
        </sec>
        <sec id="samd9l-ap.Related_Genetic_Counseling_Iss">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="samd9l-ap.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="samd9l-ap.Prenatal_Testing_and_Preimplan">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">SAMD9L</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="samd9l-ap.Resources">
        <title>Resources</title>
      </sec>
      <sec id="samd9l-ap.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="samd9l-ap.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The role of SAMD9L in human bone marrow failure and malignancies is not known with certainty. Many lines of evidence showed that SAMD9L has a role in cell proliferation, most likely as a tumor suppressor. The levels of expression of SAMD9L in breast cancer tissue and hepatocellular carcinomas are lower than in normal breast or liver tissue from the same individuals [<xref ref-type="bibr" rid="samd9l-ap.REF.li.2007.92">Li et al 2007</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.wang.2014.807">Wang et al 2014</xref>]. Somatic pathogenic variants clustered in the coding region of <italic toggle="yes">SAMD9L</italic> have been identified in hepatitis-B-related hepatocellular carcinomas [<xref ref-type="bibr" rid="samd9l-ap.REF.huang.2012.1117">Huang et al 2012</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.wang.2014.807">Wang et al 2014</xref>]. There is enhanced proliferation and colony formation of multiple hepatocellular carcinoma cell lines and increased tumorigenicity in nude mice after knockdown of <italic toggle="yes">Samd9l</italic>, the ortholog of <italic toggle="yes">SAMD9L</italic>, by siRNA or shRNA [<xref ref-type="bibr" rid="samd9l-ap.REF.wang.2014.807">Wang et al 2014</xref>]. Loss of one or both copies of <italic toggle="yes">Samd9l</italic> predisposed the mice to develop myelodysplasia [<xref ref-type="bibr" rid="samd9l-ap.REF.nagamachi.2013.305">Nagamachi et al 2013</xref>]. Studies in EBV-transformed leukocyte cell lines [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>] and transiently transfected HEK293 cells [<xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>] provided evidence that cells diploid for wild-type <italic toggle="yes">SAMD9L</italic> have a selective culture advantage over those heterozygous for mutated <italic toggle="yes">SAMD9L</italic>. The detection in multiple affected individuals in three families of hematopoietic clones with copy-neutral loss of heterozygosity for the mutated allele supports a survival advantage in vivo as well [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]. The fact that the four known pathogenic variants in SAMD9L are not in the sterile alpha motif domain suggests that the pathogenesis of <italic toggle="yes">SAMD9L</italic>-related ataxia-pancytopenia (ATXPC) syndrome is not driven by the sterile alpha motif.</p>
          <p>In individuals with <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome, marrow hypocellularity without dysplastic features reflects a toxic gain of function with suppression of precursor cell divisions. In contrast, consistent with what was observed in mice, haploinsufficiency for SAMD9L through monosomy of 7 or 7q predisposed to myelodysplasia [<xref ref-type="bibr" rid="samd9l-ap.REF.li.2012.554">Li et al 2012</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>]. Interestingly, loss of the mutated <italic toggle="yes">SAMD9</italic> allele via monosomy 7 led to myelodysplasia in two individuals with MIRAGE syndrome [<xref ref-type="bibr" rid="samd9l-ap.REF.narumi.2016.792">Narumi et al 2016</xref>]. It is speculated that transformation to acute myeloid leukemia requires additional mutations.</p>
          <p>The neurologic component of <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome possibly results from a toxic gain of function, given that neurologic deficits were not described and presumably not present in <italic toggle="yes">Samd9l</italic> knockout mice [<xref ref-type="bibr" rid="samd9l-ap.REF.li.2012.554">Li et al 2012</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">SAMD9L</italic> encompasses 18 kb of genomic DNA. The longest transcript variant <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_152703.3">NM_152703.3</ext-link> has five exons, but exons 1-4 are noncoding.</p>
          <p>Interestingly, <italic toggle="yes">SAMD9L</italic> is contiguous to paralogous gene <italic toggle="yes">SAMD9</italic>, in which defects cause the unrelated syndromes normophosphatemic familial tumoral calcinosis (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/610455">610455</ext-link>) [<xref ref-type="bibr" rid="samd9l-ap.REF.topaz.2006.759">Topaz et al 2006</xref>] and the MIRAGE syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/617053">617053</ext-link>) [<xref ref-type="bibr" rid="samd9l-ap.REF.narumi.2016.792">Narumi et al 2016</xref>].</p>
          <p><bold>Pathogenic variants.</bold> Four pathogenic variants, <xref ref-type="table" rid="samd9l-ap.T.samd9l_pathogenic_variants_d">c.2640C&#x0003e;A</xref>, <xref ref-type="table" rid="samd9l-ap.T.samd9l_pathogenic_variants_d">c.3587G&#x0003e;C</xref>, <xref ref-type="table" rid="samd9l-ap.T.samd9l_pathogenic_variants_d">c.2672T&#x0003e;C</xref>, and <xref ref-type="table" rid="samd9l-ap.T.samd9l_pathogenic_variants_d">c.2956C&#x0003e;T</xref>, have been identified to date, each in a single family [<xref ref-type="bibr" rid="samd9l-ap.REF.chen.2016.1146">Chen et al 2016</xref>, <xref ref-type="bibr" rid="samd9l-ap.REF.tesi.2017.2266">Tesi et al 2017</xref>].</p>
          <table-wrap id="samd9l-ap.T.samd9l_pathogenic_variants_d" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p><italic toggle="yes">SAMD9L</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2640C&#x0003e;A</td>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His880Gln</td>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_152703.3">NM_152703.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein/NP_689916.2">NP_689916.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2672T&#x0003e;C</td>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile891Thr</td>
                </tr>
                <tr>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2956C&#x0003e;T</td>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg986Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3587G&#x0003e;C</td>
                  <td headers="hd_h_samd9l-ap.T.samd9l_pathogenic_variants_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys1196Ser</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The 7.1 kb mRNA of transcript variant <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_152703.3">NM_152703.3</ext-link> encodes 1584 amino acids. Amino acids 14 to 79 comprise the sterile alpha motif domain.</p>
          <p><bold>Abnormal gene product.</bold> It is postulated that the four known pathogenic variants increase the function of SAMD9L protein to suppress normal hematopoiesis. The neurologic component of <italic toggle="yes">SAMD9L</italic>-related ATXPC syndrome possibly results from a toxic gain of function (see <xref ref-type="sec" rid="samd9l-ap.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>).</p>
        </sec>
      </sec>
      <sec id="samd9l-ap.References">
        <title>References</title>
        <sec id="samd9l-ap.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="samd9l-ap.Literature_Cited.reflist0">
            <ref id="samd9l-ap.REF.chen.2016.1146">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Below</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keel</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsushita</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolff</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sul</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonkowski</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taniguchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nickerson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papayannopoulou</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raskind</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <article-title>Ataxia-pancytopenia syndrome is caused by missense mutations in SAMD9L.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2016</year>
                <volume>98</volume>
                <fpage>1146</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">27259050</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.daghistani.1989.108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daghistani</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curless</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledano</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayyar</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <article-title>Ataxia-pancytopenia and monosomy 7 syndrome.</article-title>
                <source>J Pediatr.</source>
                <year>1989</year>
                <volume>115</volume>
                <fpage>108</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">2738778</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.huang.2012.1117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deng</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>KY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dai</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>ZD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>XY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fei</surname>
                    <given-names>QL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cai</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>LX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>ZG</given-names>
                  </name>
                </person-group>
                <article-title>Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma.</article-title>
                <source>Nat Genet.</source>
                <year>2012</year>
                <volume>44</volume>
                <fpage>1117</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">22922871</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.li.2007.92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macdonald</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>RY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lau</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kandel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koffman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alman</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <article-title>Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse.</article-title>
                <source>BMC Genomics.</source>
                <year>2007</year>
                <volume>8</volume>
                <fpage>92</fpage>
                <pub-id pub-id-type="pmid">17407603</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.li.1981.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hecht</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaiser-Mccaw</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baranko</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potter</surname>
                    <given-names>NU</given-names>
                  </name>
                </person-group>
                <article-title>Ataxia-pancytopenia: syndrome of cerebellar ataxia, hypoplastic anemia, monosomy 7, and acute myelogenous leukemia.</article-title>
                <source>Cancer Genet Cytogenet.</source>
                <year>1981</year>
                <volume>4</volume>
                <fpage>189</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">6947857</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.li.1978.933">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potter</surname>
                    <given-names>NU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchanan</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vawter</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whang-Peng</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosen</surname>
                    <given-names>RB</given-names>
                  </name>
                </person-group>
                <article-title>A family with acute leukemia, hypoplastic anemia and cerebellar ataxia: association with bone marrow C-monosomy.</article-title>
                <source>Am J Med.</source>
                <year>1978</year>
                <volume>65</volume>
                <fpage>933</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">283689</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.li.2012.554">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsui</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honda</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inaba</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sundberg</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Mouse Samd9l is not a functional paralogue of the human SAMD9, the gene mutated in normophosphataemic familial tumoral calcinosis.</article-title>
                <source>Exp Dermatol.</source>
                <year>2012</year>
                <volume>21</volume>
                <fpage>554</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22716256</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.nagamachi.2013.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nagamachi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsui</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asou</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aki</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takubo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolff</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honda</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inaba</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>Haploinsufficiency of SAMD9L, an endosome fusion facilitator causes myeloid malignancies in mice mimicking human diseases with monosomy 7.</article-title>
                <source>Cancer Cell.</source>
                <year>2013</year>
                <volume>24</volume>
                <fpage>305</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">24029230</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.narumi.2016.792">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Narumi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amano</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katsumata</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muroya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adachi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toyoshima</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukuzawa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyako</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinjo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohga</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ihara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinjo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urano</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitagawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsugawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okutani</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kizaki</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kihara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiga</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kenmochi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukami</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kudoh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shibata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okano</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyake</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7.</article-title>
                <source>Nat Genet.</source>
                <year>2016</year>
                <volume>48</volume>
                <fpage>792</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">27182967</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.tesi.2017.2266">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tesi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidsson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voss</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahikkala</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>SCC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komulainen-Ebrahim</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorcenco</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rundberg Nilsson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ripperger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kokkonen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryder</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fioretos</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f6;tt&#x000f6;nen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niinim&#x000e4;ki</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nilsson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pronk</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puschmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qian</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uusimaa</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moilanen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tedg&#x000e5;rd</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cammenga</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryceson</surname>
                    <given-names>YT</given-names>
                  </name>
                </person-group>
                <article-title>Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms.</article-title>
                <source>Blood.</source>
                <year>2017</year>
                <volume>129</volume>
                <fpage>2266</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">28202457</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.topaz.2006.759">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Topaz</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Indelman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chefetz</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geiger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metzker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altschuler</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bercovich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2006</year>
                <volume>79</volume>
                <fpage>759</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">16960814</pub-id>
              </element-citation>
            </ref>
            <ref id="samd9l-ap.REF.wang.2014.807">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhai</surname>
                    <given-names>YY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dai</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>KY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deng</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>ZG</given-names>
                  </name>
                </person-group>
                <article-title>SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma.</article-title>
                <source>Int J Biol Sci.</source>
                <year>2014</year>
                <volume>10</volume>
                <fpage>807</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">25076857</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="samd9l-ap.Author_Notes">
          <title>Author Notes</title>
          <p>Website: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.gs.washington.edu/faculty/raskind.htm">www.gs.washington.edu/faculty/raskind.htm</ext-link></p>
          <p>The focus of research in the Raskind laboratory is to find and study genes responsible for inherited neurologic disorders. In a long-standing collaboration with Dr. Thomas Bird, we identified <italic toggle="yes">ABCB7</italic> for X-linked sideroblastic anemia with ataxia, <italic toggle="yes">PRKCG</italic> for SCA14, <italic toggle="yes">ATP6AP2</italic> for X-linked parkinsonism with spasticity, and <italic toggle="yes">ADCY5</italic> for <italic toggle="yes">ADCY5</italic>-related dyskinesia, in addition to <italic toggle="yes">SAMD9L</italic> for ATXPC syndrome.</p>
        </sec>
        <sec id="samd9l-ap.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>1 June 2017 (sw) Review posted live</p>
            </list-item>
            <list-item>
              <p>5 December 2016 (wr) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
